- $290.11m
- $239.52m
- $152.55m
- 60
- 25
- 63
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.43 | ||
| Price to Tang. Book | 14.62 | ||
| Price to Free Cashflow | 38.36 | ||
| Price to Sales | 1.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -106.12% | ||
| Return on Equity | -78.59% | ||
| Operating Margin | -10.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.47 | 37.29 | 92.88 | 119.03 | 152.55 | 206.03 | 258.52 | 78.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual and in-home healthcare. The Company operates through two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record (EMR) system, algorithms for case-load balancing and scheduling, customer relationship management functionality, asynchronous communication, secure synchronous, cloud pharmacy and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings across various health conditions, including, dermatology, urgent and primary care, chronic care management, dermatology, chronic care management and other. Its WorkSimpli segment offers workplace and document services. This segment offers PDFSimpli an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.
Directors
- Justin Schreiber CHM (38)
- Alexander Mironov PRE (41)
- Marc Benathen CFO (41)
- Sean Fitzpatrick CEX (38)
- Brad Roberts COO (40)
- Dennis Wijnker CTO
- Maria Stan CAO (47)
- Stefan Galluppi CMO (34)
- Eric Yecies CCO (43)
- Joseph DiTrolio OTH (70)
- Nicholas Alvarez OTH (29)
- Corey Deutsch OTH (27)
- Bryant Hussey OTH (45)
- Anthony Puopolo OTH (49)
- Naveen Bhatia DRC
- Roberto Simon IND (46)
- John Strawn IND (60)
- Bertrand Velge IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 21st, 1994
- Public Since
- July 11th, 2001
- No. of Shareholders
- 304
- No. of Employees
- 207
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 42,289,990
- Address
- 236 Fifth Avenue, Suite 400, NEW YORK, 10001
- Web
- https://lifemd.com/
- Phone
- +1 9142441777
- Contact
- Yvonne Briggs
- Auditors
- Marcum LLP
Upcoming Events for LFMD
Q2 2024 LifeMD Inc Earnings Release
Q3 2024 LifeMD Inc Earnings Release
Similar to LFMD
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
What is the LifeMD share price?
As of Today at 21:49 UTC, shares in LifeMD are trading at $6.96. This share price information is delayed by 15 minutes.
How has the LifeMD share price performed this year?
Shares in LifeMD last closed at $6.96 and the price had moved by +90.68% over the past 365 days. In terms of relative price strength the LifeMD share price has outperformed the S&P500 Index by +51.73% over the past year.
What are the analyst and broker recommendations for LifeMD?
The overall consensus recommendation for LifeMD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the LifeMD dividend yield?
LifeMD does not currently pay a dividend.
Does LifeMD pay a dividend?
LifeMD does not currently pay a dividend.
When does LifeMD next pay dividends?
LifeMD does not currently pay a dividend.
How do I buy LifeMD shares?
To buy shares in LifeMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LifeMD?
As of the previous close price of $6.96, shares in LifeMD had a market capitalisation of $294.34m.
Where are LifeMD shares listed?
Here are the trading details for LifeMD:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LFMD
What kind of share is LifeMD?
Based on an overall assessment of its quality, value and momentum LifeMD is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LifeMD share price forecast for 2024?
The analyst consensus target price for shares in LifeMD is $12.83. That is 84.34% above the last closing price of $6.96.
Analysts covering LifeMD currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
What is the trend in the LifeMD share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LifeMD. Over the past six months, its share price has underperformed the S&P500 Index by -29.12%.
As of the last closing price of $6.96, shares in LifeMD were trading -9.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LifeMD PE Ratio?
The LifeMD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LifeMD?
LifeMD's management team is headed by:
- Justin Schreiber - CHM
- Alexander Mironov - PRE
- Marc Benathen - CFO
- Sean Fitzpatrick - CEX
- Brad Roberts - COO
- Dennis Wijnker - CTO
- Maria Stan - CAO
- Stefan Galluppi - CMO
- Eric Yecies - CCO
- Joseph DiTrolio - OTH
- Nicholas Alvarez - OTH
- Corey Deutsch - OTH
- Bryant Hussey - OTH
- Anthony Puopolo - OTH
- Naveen Bhatia - DRC
- Roberto Simon - IND
- John Strawn - IND
- Bertrand Velge - IND